Johnson & Johnson Signs a License Agreement with Pulmatrix to Develop Therapies for Lung Cancer
Shots:
- Pulamtrix to receive $7.2M up front- milestones up to $2M on completion of P-Ib study of RV1162/PUR1800 for patients with COPD- with on-track for year-end 2020 from J&J’s Lung Cancer. Lung Cancer Initiative to get an option to access the portfolio of kinase inhibitor targeted for lung cancer
- Post exercising an option- for RV1162/PUR1800 and portfolio of kinase inhibitors Pulmatrix will receive up to $91M as development and commercial milestones plus royalties
- Pulamtrix’s iSPERSE platform enables the formulation of drugs into small- dense- and dispersible particles for drug delivery and deep penetration into the lungs. In 2020- the company expects for P-II Pulmazole program clinical data
Click here to read full press release/ article | Ref: PRNewswire | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com